Onsdag 8 Oktober | 03:16:24 Europe / Stockholm

Bifogade filer

Kalender

Est. tid*
2025-11-21 08:40 Kvartalsrapport 2025-Q3
2025-08-29 - Kvartalsrapport 2025-Q2
2025-06-24 - Årsstämma
2025-05-19 - X-dag ordinarie utdelning ISAB 0.00 SEK
2025-05-16 - Kvartalsrapport 2025-Q1
2025-05-08 - Extra Bolagsstämma 2025
2025-02-28 - Bokslutskommuniké 2024
2024-11-20 - Kvartalsrapport 2024-Q3
2024-09-04 - Extra Bolagsstämma 2024
2024-08-28 - Kvartalsrapport 2024-Q2
2024-05-28 - Kvartalsrapport 2024-Q1
2024-05-15 - X-dag ordinarie utdelning ISAB 0.00 SEK
2024-05-14 - Årsstämma
2024-02-28 - Bokslutskommuniké 2023
2023-11-22 - Kvartalsrapport 2023-Q3
2023-08-29 - Kvartalsrapport 2023-Q2
2023-05-31 - Kvartalsrapport 2023-Q1
2023-05-15 - X-dag ordinarie utdelning ISAB 0.00 SEK
2023-05-12 - Årsstämma
2023-02-28 - Bokslutskommuniké 2022
2022-11-22 - Kvartalsrapport 2022-Q3
2022-08-29 - Kvartalsrapport 2022-Q2
2022-06-08 - X-dag ordinarie utdelning ISAB 0.00 SEK
2022-05-23 - Kvartalsrapport 2022-Q1
2022-05-06 - Årsstämma
2022-02-28 - Bokslutskommuniké 2021
2021-11-24 - Kvartalsrapport 2021-Q3
2021-08-26 - Kvartalsrapport 2021-Q2
2021-06-22 - Extra Bolagsstämma 2021
2021-06-09 - X-dag ordinarie utdelning ISAB 0.00 SEK
2021-06-08 - Årsstämma
2021-05-19 - Kvartalsrapport 2021-Q1
2021-02-25 - Bokslutskommuniké 2020
2020-11-26 - Kvartalsrapport 2020-Q3
2020-08-26 - Kvartalsrapport 2020-Q2
2020-06-12 - Extra Bolagsstämma 2020
2020-05-13 - X-dag ordinarie utdelning ISAB 0.00 SEK
2020-05-12 - Årsstämma
2020-05-07 - Kvartalsrapport 2020-Q1
2020-02-20 - Bokslutskommuniké 2019
2019-11-14 - Kvartalsrapport 2019-Q3
2019-08-22 - Kvartalsrapport 2019-Q2
2019-05-22 - Årsstämma
2019-05-16 - Kvartalsrapport 2019-Q1
2019-05-10 - X-dag ordinarie utdelning ISAB 0.00 SEK
2019-02-21 - Bokslutskommuniké 2018
2018-12-13 - Extra Bolagsstämma 2018
2018-11-15 - Kvartalsrapport 2018-Q3
2018-08-22 - Kvartalsrapport 2018-Q2
2018-05-24 - X-dag ordinarie utdelning ISAB 0.00 SEK
2018-05-23 - Årsstämma
2018-05-16 - Kvartalsrapport 2018-Q1
2018-02-22 - Bokslutskommuniké 2017
2017-11-17 - Kvartalsrapport 2017-Q3
2017-08-28 - Kvartalsrapport 2017-Q2

Beskrivning

LandSverige
ListaSpotlight
SektorHälsovård
IndustriMedicinteknik
Inhalation Sciences Sweden, ISAB, är ett forskningsbolag. Bolaget fokuserar främst på framställning och utvecklande av laboratorieinstrument. Instrumenten används för att mäta partiklar i inandningsluften och hur luftens sammansättning påverkar lungorna. Bolaget säljer produkter under varierade varumärken, främst på den europeiska marknaden. Inhalation Sciences Sweden grundades 2004 och har sitt huvudkontor i Huddinge.
2025-09-19 08:30:00

Inhalation Sciences (ISAB) is pleased to announce the continued success and positive feedback from its recurring user base, this time it is a long-standing client, the University of Liège, following the publication of new research utilizing the PreciseInhale® platform.

The research, led by Professor Didier Cataldo, focused on the formulation and performance of a novel dry powder for inhalation, combining ciclesonide and indacaterol, two agents critical for treating asthma and chronic obstructive pulmonary disease (COPD). Over the course of one year, Professor Cataldo and his team have relied on PreciseInhale® to generate high-quality and reproducible data - data now central to their latest publication (see link below and attachment to this press release).

Reflecting on his experience with PreciseInhale®, Professor Cataldo stated:

"The PreciseInhale® system proved highly valuable for generating reproducible in vitro data on the aerosolization and lung deposition properties of our dry powder formulations. The platform allowed precise generation and characterization of respirable aerosols directly from small amounts of material, an important advantage when working with early-stage formulations. The system not only allowed prediction of regional lung deposition (particle size distribution, fine particle fraction) but also provided translationally relevant insights into powder performance by assessing powders' aerosolization behaviour."

The published study demonstrates that using PreciseInhale® enabled the team to compare the performance of their advanced carrier-free powder to leading commercial products, confirming superior fine particle fractions and lung deposition, even at lower flow rates. These findings support the role of innovative in vitro technologies in driving the next generation of pulmonary therapies.

"We are extremely proud to see PreciseInhale® at the heart of groundbreaking research at the University of Liège. Our goal has always been to provide scientists and clinicians with tools that deliver not just precision, but also true translational relevance. The positive feedback from Professor Cataldo and his team affirms our commitment to enabling the advancement of inhaled therapies", says Manoush Masarrat, CEO of Inhalation Sciences.

The full publication, entitled Formulation of a dry powder for inhalation combining ciclesonide and indacaterol maleate using spray drying, can be accessed via the below link and is also attached to this press release.

Read publication here.

For more information, please contact:
Manoush Masarrat, CEO
Phone: +46 (0) 73 628 9153
E-mail: manoush.masarrat@inhalation.se

About Inhalation Sciences Sweden AB (publ)
Inhalation Sciences is a cutting-edge Contract Research Organization (CRO) specializing in inhalation drug development. Leveraging our proprietary technology platform, PreciseInhale®, we empower our clients to de-risk and accelerate their R&D pipelines by delivering high-resolution, predictive data early in the development process.